Frazier Healthcare Partners announced the planned addition of Albert Cha, M.D., Ph.D. as Managing Partner on the Life Sciences team. He has over 20 years of experience investing in public and private biopharmaceutical...
BRIDGEWATER, N.J., Sept. 09, 2020 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will present...
Will commence trading under new Nasdaq Ticker “VYNE”, September 8, 2020
Company will commence trading under new ticker “VYNE” on September 8, 2020
Conference Call Today at 8:30am Eastern Time
BRIDGEWATER, N.J., July 28, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing...
BRIDGEWATER, N.J., June 05, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (“Menlo”) (Nasdaq: MNLO), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies...
BRIDGEWATER, N.J., June 04, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (“Menlo”) (Nasdaq: MNLO), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies...
The Company plans to present trial data along with a proposed Phase 3 development program in an End of Phase 2 meeting with the FDA before the end of this year
ZILXI™ Now Approved for Inflammatory Lesions of Rosacea in Adults